Fig. 3: Clinicopathological predictors of outcome by treatment strategy in the MDACC primary cohort (n = 1133). | Nature Communications

Fig. 3: Clinicopathological predictors of outcome by treatment strategy in the MDACC primary cohort (n = 1133).

From: Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer

Fig. 3

Forest plot of clinicopathologic variables and association with a, progression-free survival (PFS) and b, overall survival (OS) on univariate (black) and multivariate (pink) analysis, stratified by ICI-monotherapy (ICI-mono, left panel) and ICI-chemotherapy (ICI-chemo, right panel). Data are presented as the hazard ratio with error bars showing 95% confidence interval. Cox proportional hazards regression models were applied to calculate the hazard ratio. c, d Forest plot of difference in treatment effect between ICI-mono and ICI-chemo on c PFS and d OS. Data are presented as the treatment effect estimates with error bars showing the 95% confidence interval; subtee R package was used to generate treatment effect estimates. e Kaplan–meier plot comparing PFS (left panel) and OS (right panel) in patients treated with ICI-mono vs ICI-chemo, stratified by smoking status. Source data are provided as a Source Data file.

Back to article page